Get the Stockscreener App
318.53
0.84%
-2.1341
Alnylam Pharmaceuticals Inc stock is traded at $318.53, with a volume of 578.67K.
It is down -0.84% in the last 24 hours and down -0.63% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$320.66
Open:
$317.25
24h Volume:
578.67K
Relative Volume:
0.39
Market Cap:
$42.24B
Revenue:
$3.71B
Net Income/Loss:
$313.75M
P/E Ratio:
141.12
EPS:
2.2571
Net Cash Flow:
$465.38M
1W Performance:
-2.18%
1M Performance:
-0.63%
6M Performance:
-34.05%
1Y Performance:
+30.04%
1-Day Range:
$313.12
$320.00
1-Week Range:
$312.09
$328.28
52-Week Range:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
318.48 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.79 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.08 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.24 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ONC
Beone Medicines Ltd Adr
|
297.56 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-07-26 | Resumed | Oppenheimer | Outperform |
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics - simplywall.st
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - Yahoo Finance
ALNYLAM PHARMACEUTICALS Executives Sell Shares - TradingView
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After Recent Share Price Pullback - simplywall.st
Victory Capital Management Inc. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal - Pharmaceutical Technology
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - Yahoo Finance
Alnylam Updates Hypertension Pipeline And AMVUTTRA Access Shape Valuation View - Sahm
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Responsive Playbooks and the ALNY Inflection - Stock Traders Daily
Tenaya To Evaluate Genetic Cardiovascular Targets For Alnylam - Citeline News & Insights
Alnylam board creates $18M incentive award to keep CEO through 2029 - The Business Journals
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Benzinga
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - bioworld.com
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - Investing News Network
Tenaya wins support from Alnylam in cardio disease pact - Endpoints News
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - marketscreener.com
Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam - marketscreener.com
Alnylam Pharmaceuticals (ALNY) Forms Partnership for Cardiovascu - GuruFocus
Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development - PR Newswire
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration - TipRanks
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - Seeking Alpha
Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics - marketscreener.com
Tenaya Therapeutics Enters into Research Collaboration with - GlobeNewswire
Focus Partners Advisor Solutions LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
CI Investments Inc. Buys 3,109 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Canada’s AMVUTTRA Reimbursement Tailwind Altering The Investment Case For Alnylam Pharmaceuticals (ALNY)? - Yahoo Finance
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells 6,799 Shares of Stock - MarketBeat
Alnylam CEO Greenstreet sells $2.23 million in stock - Investing.com India
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $523,584.70 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Pushkal Garg Sells 1,717 Shares - MarketBeat
Alnylam (NASDAQ: ALNY) EVP receives new options and RSUs - Stock Titan
Alnylam Grants CEO New Performance-Based Equity Award - TipRanks
Alnylam Reimbursement Win And Trial Progress Versus Current Valuation Signals - Yahoo Finance
Alnylam Pharmaceuticals grants performance-based equity award to CEO By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals grants performance-based equity award to CEO - Investing.com Nigeria
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Presents a Growth Story at a Technical Turning Point - ChartMill
Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors - BioSpace
Pushkal Garg (ALNY) reports sale of 4,627 shares for $1.53M - Stock Titan
The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following AMVUTTRA Uptake And Canada Reimbursement News - simplywall.st
Rafferty Asset Management LLC Sells 15,045 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Elo Mutual Pension Insurance Co Purchases 3,738 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. - Yahoo Finance
ALNY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Alnylam (NASDAQ: ALNY) CEO converts 5,921 RSUs into common stock - Stock Titan
Alnylam (ALNY) CFO receives 1,908 shares as final RSU tranche vests - Stock Titan
Alnylam (ALNY) CCO receives 1,666 shares from RSU vesting - Stock Titan
Alnylam (NASDAQ: ALNY) R&D chief sells 4,627 shares under plan - Stock Titan
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: An 84.90% Revenue Surge and 37.27% Upside Potential - DirectorsTalk Interviews
Paroxysmal Nocturnal Hemoglobinuria Market: Expanding Revenue Landscape to 2034 – DelveInsight | Alexion Pharma, Hoffmann-La Roche, Novartis, Regeneron Pharma, AKARI Therapeutics, AstraZeneca - Barchart.com
Alnylam Pharmaceuticals receives positive recommendation from Canada's drug agency for public reimbursement of Amvuttra - marketscreener.com
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | EVP Chief R&D |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
21,097 |
| Greenstreet Yvonne | Chief Executive Officer |
Mar 04 '26 |
Sale |
323.08 |
2,933 |
947,581 |
95,695 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,468 |
797,351 |
61,805 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
34,297 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 05 '26 |
Sale |
323.98 |
658 |
213,177 |
20,569 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 04 '26 |
Sale |
323.08 |
633 |
204,508 |
21,227 |
1.06%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):